We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Montelukast on Difficulty in Breathing After Exercise in Pediatric Patients (MK0476-377)(COMPLETED)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00534976
First Posted: September 26, 2007
Last Update Posted: April 6, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
Results First Submitted: March 11, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Crossover Assignment;   Masking: Double (Participant, Investigator);   Primary Purpose: Treatment
Condition: Exercise-induced Bronchoconstriction (EIB)
Interventions: Drug: Comparator: montelukast sodium
Drug: Comparator: Comparator: placebo (unspecified)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Of the 364 participants screened for inclusion, 298 participants were excluded during screening and were not randomized. The remaining 66 participants met inclusion criteria and were randomly allocated to one of the two treatment sequences.

Reporting Groups
  Description
Montelukast/ Placebo In Period I (screening period/ placebo run-in) participants received a single-blind dose of matching-image placebo. In Period II, participants 4-5 years of age were randomized to receive one Montelukast 4-mg chewable tablet (single dose). Period III was the crossover to one matching placebo 4-mg chewable tablet (single dose) after a 3- to 7-day washout period. No participants 4-5 years of age were randomized, so the 4-mg doses were not dispensed. Participants 6-14 years of age were randomized to receive one Montelukast 5-mg chewable tablet (single dose) in Period II, crossing over to one matching placebo 5-mg chewable tablet (single dose) in Period III after a 3- to 7-day washout period.
Placebo/ Montelukast In Period I (screening period/ placebo run-in) participants received a single-blind dose of matching-image placebo. In Period II, participants 4-5 years of age were randomized to receive one placebo 4-mg chewable tablet (single dose). Period III was the crossover to one Montelukast 4-mg chewable tablet (single dose) after a 3- to 7-day washout period. No participants 4-5 years of age were randomized, so the 4-mg doses were not dispensed. Participants 6-14 years of age were randomized to receive one placebo 5-mg chewable tablet (single dose) in Period II, crossing over to one Montelukast 5-mg chewable tablet (single dose) in Period III after a 3- to 7-day washout period.

Participant Flow for 3 periods

Period 1:   Period 1: Placebo Run-in
    Montelukast/ Placebo   Placebo/ Montelukast
STARTED   33   33 
COMPLETED   33   33 
NOT COMPLETED   0   0 

Period 2:   Period 2: Treatment Montelukast/ Placebo
    Montelukast/ Placebo   Placebo/ Montelukast
STARTED   33   33 
COMPLETED   33   32 
NOT COMPLETED   0   1 
Protocol Violation                0                1 

Period 3:   Period 3: Crossover Placebo/ Montelukast
    Montelukast/ Placebo   Placebo/ Montelukast
STARTED   33   32 
COMPLETED   31   32 
NOT COMPLETED   2   0 
Physician Decision                1                0 
Withdrawal by Subject                1                0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Montelukast/ Placebo In Period I (screening period/ placebo run-in) participants received a single-blind dose of matching-image placebo. In Period II, participants 4-5 years of age were randomized to receive one Montelukast 4-mg chewable tablet (single dose). Period III was the crossover to one matching placebo 4-mg chewable tablet (single dose) after a 3- to 7-day washout period. No participants 4-5 years of age were randomized, so the 4-mg doses were not dispensed. Participants 6-14 years of age were randomized to receive one Montelukast 5-mg chewable tablet (single dose) in Period II, crossing over to one matching placebo 5-mg chewable tablet (single dose) in Period III after a 3- to 7-day washout period.
Placebo/ Montelukast In Period I (screening period/ placebo run-in) participants received a single-blind dose of matching-image placebo. In Period II, participants 4-5 years of age were randomized to receive one placebo 4-mg chewable tablet (single dose). Period III was the crossover to one Montelukast 4-mg chewable tablet (single dose) after a 3- to 7-day washout period. No participants 4-5 years of age were randomized, so the 4-mg doses were not dispensed. Participants 6-14 years of age were randomized to receive one placebo 5-mg chewable tablet (single dose) in Period II, crossing over to one Montelukast 5-mg chewable tablet (single dose) in Period III after a 3- to 7-day washout period.
Total Total of all reporting groups

Baseline Measures
   Montelukast/ Placebo   Placebo/ Montelukast   Total 
Overall Participants Analyzed 
[Units: Participants]
 33   33   66 
Age 
[Units: Years]
Mean (Standard Deviation)
 10.9  (2.3)   11.5  (1.8)   11.2  (2.1) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
     
Female      14  42.4%      15  45.5%      29  43.9% 
Male      19  57.6%      18  54.5%      37  56.1% 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Maximum Percent Fall in Forced Expiratory Volume in 1 Second (FEV1) After Exercise Challenge at 2 Hours Postdose   [ Time Frame: Pre-exercise baseline and 0-60 minutes after the exercise challenge performed 2 hours post-dose ]

2.  Secondary:   Maximum Percent Fall in FEV1 After Exercise Challenge at 24 Hours Post-dose   [ Time Frame: Pre-exercise baseline and 0-60 minutes after the exercise challenge performed 24 hours post-dose ]

3.  Secondary:   Area Under the Curve for FEV1 Percent Fall From Pre-exercise Baseline to 60 Minutes Following Exercise Challenge (AUC0-60 Min) at 2 Hours Post-dose   [ Time Frame: Pre-exercise baseline to 60 minutes after the exercise challenge performed 2 hours post-dose ]

4.  Secondary:   Area Under the Curve for FEV1 Percent Fall From Pre-exercise Baseline to 60 Minutes Following Exercise Challenge (AUC0-60 Min) at 24 Hours Post-dose   [ Time Frame: Pre-exercise baseline to 60 minutes after the exercise challenge performed 24 hours post-dose ]

5.  Secondary:   Time to Recovery From Maximum Percent Fall in FEV1 at 2 Hours Post-dose   [ Time Frame: 0-60 minutes and 0-90 minutes after the exercise challenge at 2 hours postdose ]

6.  Secondary:   Time to Recovery From Maximum Percent Fall in FEV1 at 24 Hours Post-dose   [ Time Frame: 0-60 minutes and 0-90 minutes after the exercise challenge at 24 hours postdose ]

7.  Secondary:   Number of Participants Requiring Rescue Medication at 2 Hours Postdose   [ Time Frame: 0-90 minutes after the exercise challenge at 2 hours postdose ]

8.  Secondary:   Number of Participants Requiring Rescue Medication at 24 Hours Postdose   [ Time Frame: 0-90 minutes after the exercise challenge at 24 hours postdose ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Senior Vice President, Global Clinical Development
Organization: Merck Sharp & Dohme Corp
e-mail: ClinicalTrialsDisclosure@merck.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00534976     History of Changes
Other Study ID Numbers: 0476-377
2007_586
First Submitted: September 21, 2007
First Posted: September 26, 2007
Results First Submitted: March 11, 2011
Results First Posted: April 7, 2011
Last Update Posted: April 6, 2017